Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phage KPN2177
- Development stage
- Preclinical
- Lead developer
- Università degli Studi di Verona
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
phage KPN2177 (also known as bacteriophage KPN2177) is a strictly lytic bacteriophage isolated from wastewater at Verona University Hospital [P2702]. It has a genome size of approximately 50 kb encoding 85 proteins [P2702]. Phage KPN2177 is being investigated for its antibacterial activity against multidrug-resistant (MDR) and β-lactamase-producing *Klebsiella pneumoniae* strains, including carbapenemase VIM-1, KPC, and NDM producers [P2702]. In preclinical studies, phage KPN2177 has demonstrated synergistic bactericidal activity when combined with the carbapenem antibiotic meropenem, showing enhanced and prolonged inhibition of bacterial growth and preventing the regrowth typically observed with phage-only treatments [P2702].
- Other names
- bacteriophage KPN2177
Beyond the preview
Go deeper on phage KPN2177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phage KPN2177.